10058-F4: Advanced c-Myc-Max Dimerization Inhibitor for Precision Apoptosis Research

Introduction

Targeting oncogenic transcription factors remains a significant challenge in cancer biology. The c-Myc transcription factor, a master regulator of cell growth, differentiation, and apoptosis, is frequently dysregulated in malignancies. Its activity depends on the formation of the c-Myc-Max heterodimer, which orchestrates transcriptional programs driving proliferation and survival. 10058-F4 (SKU: A1169), a novel small-molecule, cell-permeable c-Myc-Max dimerization inhibitor, offers researchers an incisive tool to dissect and modulate these pathways with high specificity. This article provides a technical, application-focused analysis of 10058-F4, highlighting its mechanism, unique research applications, and how it advances the landscape beyond current literature.

Mechanism of Action: Disruption of the c-Myc/Max Heterodimerization Pathway

c-Myc exerts its oncogenic effects by binding Max, forming a heterodimer that targets E-box DNA elements and activates gene expression programs essential for cell cycle progression and metabolic adaptation. 10058-F4 is a first-in-class, small-molecule c-Myc inhibitor that selectively disrupts this critical dimerization interface. By binding to c-Myc, 10058-F4 blocks its association with Max, thus preventing DNA binding and subsequent transcriptional activation (Kotian et al., 2024).

This blockade initiates a cascade of effects:

• Suppression of c-Myc-driven transcription: Inhibition of c-Myc/Max heterodimer formation leads to decreased expression of c-Myc target genes involved in proliferation and survival.
• Reduction in c-Myc mRNA and protein: Feedback mechanisms further downregulate c-Myc expression at both transcriptional and translational levels.
• Induction of mitochondrial apoptosis: The intervention triggers cell cycle arrest and apoptosis, notably via modulation of Bcl-2 family proteins and cytochrome C release.

Recent research has illuminated further mechanistic complexity. Kotian et al. demonstrated that c-Myc-Max complexes actively prevent polycomb repressive complex 2 (PRC2)-mediated silencing of TERT, the catalytic subunit of telomerase, by maintaining active chromatin at the TERT promoter. Inhibition of c-Myc-Max dimerization by 10058-F4 led to a rapid gain of repressive histone marks (H3K27me3) at TERT, reduced telomerase transcription, and diminished MAX recruitment—linking c-Myc/Max disruption not only to apoptosis but also to telomere maintenance in stem and cancer cells.

Distinctive Physicochemical Properties and Handling

10058-F4 is chemically defined as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one, with a molecular weight of 249.35. It is supplied as a solid, soluble at ≥24.9 mg/mL in DMSO and ≥2.64 mg/mL in ethanol, but insoluble in water, necessitating careful handling and prompt use of prepared solutions. Storage at -20°C is recommended to preserve integrity. These properties make it suitable for both in vitro and in vivo applications, from apoptosis assays to xenograft cancer models.

Comparative Analysis: 10058-F4 Versus Alternative c-Myc Inhibition Strategies

While several strategies exist to inhibit c-Myc activity—including genetic knockdown, peptide inhibitors, and newer PROTACs—10058-F4 offers key advantages:

• Direct, reversible inhibition of c-Myc-Max dimerization without requiring genetic manipulation or permanent protein degradation.
• Cell-permeability, enabling rapid and controlled modulation in both established cell lines and primary cells.
• Proven efficacy in apoptosis assay workflows, with robust induction of mitochondrial apoptosis in acute myeloid leukemia (AML) cell lines (e.g., HL-60, U937, NB-4) at 100 μM after 72 hours.
• In vivo translational relevance, as demonstrated by tumor growth inhibition in prostate cancer xenograft models (DU145, PC-3) in SCID mice.

In contrast, genetic approaches may not fully recapitulate the acute, pharmacologically relevant inhibition provided by small molecules. Peptide-based inhibitors often suffer from poor cell permeability and stability. As described in existing guides such as "10058-F4: Advanced c-Myc-Max Dimerization Inhibitor for A...", workflow optimization and troubleshooting are important; however, this article emphasizes the mechanistic integration and translational scope of 10058-F4, especially as it relates to chromatin regulation and telomere biology—a perspective not fully explored in prior content.

Innovative Applications: From AML to Prostate Cancer Xenograft Models

Acute Myeloid Leukemia Research

AML remains a paradigm of c-Myc-driven malignancy, with high c-Myc expression correlating with poor prognosis. 10058-F4’s ability to induce apoptosis in AML cell lines has been quantitatively validated: following exposure to 100 μM for 72 hours, HL-60, U937, and NB-4 cells undergo dose-dependent apoptosis, with upregulation of pro-apoptotic Bcl-2 family proteins and release of cytochrome C—a hallmark of engagement of the mitochondrial apoptosis pathway. These features make 10058-F4 a cornerstone tool for apoptosis assay optimization and mechanistic studies in hematological malignancies.

Prostate Cancer Xenograft Models

Translating in vitro findings to in vivo settings, 10058-F4 has demonstrated tumor growth inhibition in SCID mice bearing human prostate cancer xenografts (DU145, PC-3). While efficacy may be variable and context-dependent, these studies establish the compound’s suitability for investigating c-Myc/Max heterodimer disruption pathways in solid tumor biology and preclinical drug development. Its unique solubility profile in DMSO and ethanol facilitates intravenous administration in animal models.

Stem Cell and Telomerase Regulation Research

A major advance, highlighted in the Kotian et al. 2024 study, is the demonstration that c-Myc-Max complexes protect TERT from polycomb repression in human pluripotent stem cells. Application of 10058-F4, even at low doses, induced rapid deposition of H3K27me3 at the TERT promoter, downregulating telomerase expression and providing a new mechanistic link between c-Myc/Max activity and stem cell self-renewal. This insight expands the utility of 10058-F4 beyond oncology, supporting its use in developmental biology and regenerative medicine.

Content Differentiation: Integrating Chromatin and Telomere Dynamics

The current literature on 10058-F4, including articles like "Disrupting c-Myc/Max Dimerization: Strategic Pathways and..." and "10058-F4: A Small-Molecule c-Myc Inhibitor Transforming A...", have provided foundational perspectives on the role of c-Myc-Max dimerization inhibitors in apoptosis and telomerase regulation, often focusing on workflow implementation and translational strategy. This article builds upon those foundations by specifically integrating new evidence on chromatin state modulation at the TERT promoter—bridging oncogenic signaling, epigenetic regulation, and telomere biology in a unified model. By leveraging the latest mechanistic insights from the core scientific reference, it offers researchers a deeper understanding of how c-Myc-Max disruption reprograms both gene expression and chromatin landscapes, with implications for cancer, stem cell, and aging research.

Practical Considerations: Handling, Storage, and Product Sourcing

10058-F4’s performance as a cell-permeable c-Myc inhibitor for apoptosis research depends on appropriate handling. As supplied by APExBIO, the solid compound should be aliquoted, dissolved in DMSO or ethanol immediately before use, and stored at -20°C. Solutions are not recommended for long-term storage, as potency may diminish. Researchers are encouraged to consult the official product page for technical specifications, safety data, and ordering information.

Conclusion and Future Outlook

10058-F4 stands out as a highly specialized, small-molecule c-Myc-Max dimerization inhibitor with broad utility across cancer, stem cell, and telomere biology research. Its direct, reversible inhibition of the c-Myc/Max heterodimerization pathway not only advances apoptosis assay development in acute myeloid leukemia and solid tumor models but also enables exploration of chromatin dynamics and telomerase regulation. With insights from recent mechanistic studies, including modulation of PRC2 activity and TERT expression, 10058-F4 is positioned as a next-generation tool for unraveling the complexity of oncogenic transcription factors and their epigenetic networks.

As the field progresses, integrating 10058-F4 with complementary techniques—such as chromatin immunoprecipitation, transcriptomics, and single-cell epigenomics—will illuminate new therapeutic targets and strategies. For researchers seeking to probe the intricacies of c-Myc-driven oncogenesis, mitochondrial apoptosis, and epigenetic regulation, 10058-F4 remains an indispensable resource.